European stocks climb; U.S.-EU trade agreement, earnings and Fed meeting in focus

European equities rose on optimism surrounding the new U.S./EU trade agreement, which includes a 15% U.S. tariff on most EU goods, drawing criticism from EU leaders despite averting a full-blown trade war. Corporate results were mixed: Stellantis provided optimistic second-half guidance, Barclays reported a 23% H1 profit increase, while Philips' net income fell 47% due to a prior-year one-time gain, though operating metrics improved. Concurrently, oil prices climbed ahead of the Federal Reserve's policy meeting, where rates are expected to hold steady amid debate over potential cuts.

Analysis

European equities are experiencing a tentative uplift following a U.S./EU trade agreement that reduces immediate uncertainty, yet introduces a contentious 15% U.S. tariff on most EU goods. This deal has drawn sharp criticism from French and German officials, who anticipate significant economic damage, suggesting that underlying trade tensions and potential headwinds for the European economy persist. Corporate earnings present a bifurcated landscape. Stellantis (STLA) has issued optimistic second-half guidance, forecasting revenue growth and improved industrial free cash flow after a significant €3 billion cash burn in the first half. In the financial sector, Barclays (BARC) reported a better-than-expected 23% rise in first-half profit, benefiting from heightened market volatility. Conversely, results from other sectors require deeper inspection: AstraZeneca (AZN) beat Q2 earnings but maintained its full-year forecast, citing pricing and trade risks, while Philips (PHG) saw a 47% drop in net income due to the absence of a prior-year one-time gain, even as key operating metrics like margins and cash flow improved. Similarly, Sika (SIKA) and Air Liquide (AIQUY) demonstrated operational resilience, raising margins despite revenue headwinds or through effective cost controls. This corporate activity unfolds as oil prices rise on a more positive demand outlook and ahead of a Federal Reserve meeting where interest rates are expected to hold steady, though the debate over future cuts remains a key focus.

Key Decisions for Investors

• Given the contentious nature of the U.S./EU trade deal, investors should monitor the real economic impact on European exporters, as official government criticism signals potential for future friction and negative revisions to the bloc's outlook.
• Stellantis's optimistic second-half guidance presents a potential turnaround narrative, but validation will depend on its ability to reverse the €3 billion first-half cash burn and execute on its projected recovery.
• For companies like Philips and AstraZeneca, investors must look beyond headline figures; Philips' improved operating metrics signal underlying health despite a net income decline, whereas AstraZeneca's cautious guidance tempers its strong Q2 earnings beat.
• The 23% profit jump at Barclays, driven by trading volatility, warrants scrutiny to determine if it reflects a sustainable operational strength or a one-off benefit from a turbulent macro environment.
• The upcoming Federal Reserve policy meeting is a critical short-term catalyst, as any dovish shift in language regarding future rate cuts could significantly influence currency valuations and equity sentiment, particularly for European markets.